You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 27, 2024

Claims for Patent: 4,499,084

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 4,499,084

Title:	Ara-A Antiviral composition and method of administering the same
Abstract:	There is disclosed an antiviral composition for treating herpes simplex virus disease and a method for administering the antiviral composition by topical application on the infected portion of the human body. The antiviral composition comprises a mixture of an antiviral agent, ara-A, and a solvent carrier medium, dimethyl sulfoxide.
Inventor(s):	Dixon; Glen J. (Stone Mountain, GA)
Assignee:
Application Number:	06/463,467
Patent Claims:	1. An antiviral composition for treating herpes simplex virus disease in humans comprising a solvent carrier which will translocate throughout the body and penetrate cell walls and an antiviral agent which interferes with viral deoxynucleic acid synthesis causing inhibition of viral maturation wherein the solvent carrier includes dimethyl sulfoxide and water and wherein the antiviral agent is ara-A. 2. A method for treating herpes simplex virus disease in humans comprising the step of topically applying every two to four hours to infected portions of the human body an antiviral composition comprising a solvent carrier which will translocate throughout the body and penetrate cell walls and an antiviral agent which interferes with viral deoxynucleic acid synthesis causing inhibition of viral maturation, wherein the solvent carrier includes dimethyl sulfoxide and wherein the antiviral agent is ara-A. 3. The method for treating herpes simplex virus disease in humans of claim 2, wherein the antiviral composition further comprises a local anesthetic. 4. The method for treating herpes simplex virus disease in humans of claim 2, wherein the antiviral composition further comprises a gel forming agent. 5. An antiviral composition for treating herpes simplex virus disease in humans comprising a solvent carrier which will translocate throughout the body and penetrate cell walls and an antiviral agent which interferes with viral deoxynucleic acid synthesis causing inhibition of viral maturation, wherein the solvent carrier includes dimethyl sulfoxide and water and wherein the antiviral agent is purine analog of ara-A and is selected from the group consisting of acyclovir and ribavirin. 6. A method for treating herpes simplex virus disease in humans comprising the step of topically applying every two to four hours to infected portions of the human body an antiviral composition comprising a solvent carrier which will translocate throughout the body and penetrate cell walls and an antiviral agent which interferes with viral deoxynucleic acid synthesis causing inhibition of viral maturation, wherein the solvent carrier includes dimethyl sulfoxide and wherein the antiviral agent is a purine analog of ara-A and is selected from the group consisting of acyclovir and ribavirin. 7. The antiviral composition of claim 1, having the following proportions by percentage weight: ara-A is 0.1 to 10.0 percent of the total composition, dimethyl sulfoxide is 50 percent to less than 100 percent of the solvent carrier, and demineralized water is greater than 0 percent up to 50 percent of the solvent carrier. 8. The antiviral composition of claim 1, having the following approximate proportions: 1.0 gram of ara-A, 70.0 milliliters dimethyl sulfoxide, and 30.0 milliliters demineralized water. 9. The method for treating herpes simplex virus disease in humans of claim 2, wherein solvent carrier further includes water. 10. The method for treating herpes simplex virus disease in humans of claims 2 or 9, having the following proportions by percentage weight: ara-A is 0.1 to 10.0 percent of the total composition, dimethyl sulfoxide is 50 to 100 percent of the solvent carrier, and demineralized water is 0 to 50 percent of the solvent carrier. 11. The method for treating herpes simplex virus disease in humans of claim 9, wherein the antiviral composition comprises the following approximate proportions: 1.0 gram of ara-A, 70.0 milliliters dimethyl sulfoxide, and 30.0 milliliters demineralized water.

Details for Patent 4,499,084

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Hoffmann-la Roche Inc.	PEGASYS COPEGUS COMBINATION PACK	peginterferon alfa-2a and ribavirin		125083	June 04, 2004	⤷ Subscribe	2039-03-29
Schering Corporation A Subsidiary Of Merck & Co., Inc.	PEGINTRON/ REBETOL COMBO PACK	peginterferon alfa-2b and ribavirin		125196	June 13, 2008	⤷ Subscribe	2039-03-29
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.